Swedish Orphan Biovitrum just released its Q3 2026 results and the headline is simple. Earnings power is rising while the share price is still playing catch up. The stock closed at SEK478.2 on 28 October, capping a 1 week gain of about 4.3% and roughly 8.8% over the past month, a modest reaction for a rare disease group that reported SEK9,124m in quarterly revenue and SEK6.76 in basic earnings per share.
Impressed by Swedish Orphan Biovitrum's earnings power but want more ideas where solid fundamentals meet disciplined pricing? Compare SOBI's setup with our curated list of solid balance sheet and fundamentals stocks (207 results) .
Q3 2026 Earnings Summary
-
Total Revenue (Q3 2026 vs Q3 2025):SEK 9,124m vs. SEK 7,776m (up 17.3%).
-
Net Income (Excl. Extra Items, Q3 2026 vs Q3 2025):SEK 2,350m vs. a loss of SEK 2,894m (swing back to profit).
-
Basic EPS (Q3 2026 vs Q3 2025):SEK 6.76 vs. a loss of SEK 8.40 (return to positive earnings per share).
-
Adjusted EBITA Margin (Q3 2026 vs prior year commentary):45% in Q3 2026 vs. 40% year to date in 2026 (margin tracking toward the upper end of guidance).
Revenue is racing ahead of Sobi's own 2030 growth plan. Ask Charlie what makes Sobi confident in its 2030 target .
Evaluating Sobi's Launch-Led Bull Case
The upbeat story around Swedish Orphan Biovitrum hangs on whether early launches can shoulder more of the heavy lifting already.
"Altuvoct is gaining traction in major hemophilia A markets, with reimbursement in all key European countries and market shares above 60% in prophylaxis in Germany, supporting continued revenue growth and scale benefits for margins."
Q3 data backs this up. The hemophilia A franchise grew 48% at constant FX and Altuvoct sales rose very strongly, helped by launches in 32 countries. That push fed into a 45% adjusted EBITA margin in the quarter, above the year-to-date 40%, which suggests the rare disease model is already generating operating leverage rather than just consuming launch spend.
One Narrative has put a figure on that disagreement. → See the Narrative with its lower Fair Value, assumptions and all .
Swedish Orphan Biovitrum Margins: Ambition Meets Spending Reality
The bearish worry is that Swedish Orphan Biovitrum is leaning on margin optimism that future launch costs may not support.
"Expansion into severe hypertriglyceridemia and broader cardiometabolic use for Tryngolza relies on specialist center adoption and later diffusion into community practice. Slower than expected physician uptake or payer restrictions could leave sales below current expectations, limiting operating leverage and EBITA margin improvement."
Q3 shows a 45% adjusted EBITA margin against unchanged full year guidance in the mid to high 30s, which keeps that concern alive. Management explicitly flagged heavier Q4 launch and R&D spend. Tryngolza is still pre revenue, so today's profitability comes from the existing portfolio rather than proof that future cardiometabolic rollouts can fund themselves.
Hunt Beyond Swedish Orphan Biovitrum
Swedish Orphan Biovitrum just showed how earnings and share price can move on different timetables. The real opportunity could sit in stocks the market has not fully repriced yet.
-
Company 1 - 20% below our estimate - expands complex generics and ex U.S. formulations while rising operating cash flow supports future product filings and launches.
-
Company 2 - 42% below our estimate - sells oncology software that embeds as the hardware agnostic control layer while recurring support contracts replace one off licenses.
-
Company 3 - 34% below our estimate - grows an advisory platform where newly hired senior bankers convert a record mandate pipeline into higher fee capital markets and restructuring work.
Those are three of them. See the full list of 195 companies trading below our fair value estimates →
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SOBI.ST .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
